scholarly journals PRS29 Cost-Utility Analysis of Fixed Dose Combination (FDC) of Indacaterol Acetate (IND) and Mometasone Furoate (MF) As a Maintenance Treatment of Asthma in Patients not Adequately Controlled with Inhaled Corticosteroids and Inhaled Short Acting beta2-Agonists

2020 ◽  
Vol 23 ◽  
pp. S721-S722
Author(s):  
P.P. Mangia ◽  
L. Pradelli ◽  
O. Gallo ◽  
D. Ritrovato ◽  
S. Gupta
2013 ◽  
Vol 10 (4) ◽  
pp. 60-64
Author(s):  
A V Emelyanov

The review focused on mometasone furoate/formoterol (MF/F), a new fixed dose combination (Zenhale, MDI 50/5, 100/5 and 200/5 mcg/dose) for treatment of asthma in adults and children 12 years of age and older. New combination should be used for patients not adequately controlled with inhaled corticosteroids (ICS) and «as needed» inhaled short acting β 2-agonist or those whose disease severity warrants initiation of treatment with two maintenance therapies. It may be also used in patients already adequately controlled on both ICS and long-acting β 2-agonist. Data from randomized placebo controlled clinical trials confirm that MF/F has fast onset of action, reduces number of exacerbations, improves lung function, quality of life and asthma control. MF/F has a good safety profile.


1995 ◽  
Vol 16 (1) ◽  
pp. 17-40 ◽  
Author(s):  
Mark S Kamlet ◽  
Nancy Paul ◽  
Joel Greenhouse ◽  
David Kupfer ◽  
Ellen Frank ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document